10-Q quarterly report · filed Nov 4, 2026

Adaptive Biotechnologies Corp (ADPT) Q3 2026 10-Q Quarterly Report

Short answer

Adaptive Biotechnologies Corp (ADPT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $84M (down 10.7% year over year) with net income of $3M.

Q3 2026 key financials · XBRL

Revenue
$84M
−10.7% YoY · +17.3% QoQ
Net income
$3M
−69.9% YoY · +107.2% QoQ
Operating margin
-0.5%
EPS (diluted)
$0.02
−71.4% YoY · +108.0% QoQ

Source: XBRL data from the Adaptive Biotechnologies Corp (ADPT) Q3 2026 10-Q on SEC EDGAR. USD.

Adaptive Biotechnologies Corp Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Q3 revenue $83.9M, down $10.1M or 11% YoY
  • Operating margin (0.5%) vs 10.9% YoY, net income $2.9M vs $9.5M
  • Best segment MRD: revenue $72.6M, Adjusted EBITDA $15.1M vs $7.0M
  • Worst segment Immune Medicine: revenue $11.3M vs $37.2M, Adjusted EBITDA $3.2M vs $24.1M
  • Cash, equivalents and securities $400.2M vs $240.2M, nine-month operating cash use $6.3M vs $48.0M; near-term Immune Medicine revenue expected to decrease

Risk Factors

  • No material changes to risk factors from the February 26, 2026 10-K or August 4, 2026 10-Q
  • Business risk: Rapidly changing operating environment could materially affect results
  • Liquidity risk: Combined risks could adversely affect financial condition or liquidity
  • Market risk: Adverse developments could reduce the value of common stock

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Adaptive Biotechnologies Corp quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.